Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Decision and Details
Absorption-type company split involving the NASH treatment app business
Decision26 June 2026 (date the corporate split agreement was executed)
Implementation1 September 2026 (effective date; completed)
Going forwardThe company plans to apply for registration of the changes prescribed in Article 923 of the Companies Act without delay after 1 September 2026.
AmountTransferred assets: ¥58 million (estimated); transferred liabilities: ¥108 million (estimated)
Reason
Pursuant to the company split agreement, the rights and obligations held by the company effecting the absorption-type company split in connection with the NASH treatment app business were transferred to its wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd.
| Item | Details |
|---|---|
| Matter Covered | Absorption-type company split involving the NASH treatment app business |
| Decision Date | 26 June 2026 (date the corporate split agreement was executed) |
| Implementation Date | 1 September 2026 (effective date; completed) |
| Amount | Transferred assets: ¥58 million (estimated); transferred liabilities: ¥108 million (estimated) |
| Reason | Pursuant to the company split agreement, the rights and obligations held by the company effecting the absorption-type company split in connection with the NASH treatment app business were transferred to its wholly owned subsidiary, Sawai Pharmaceutical Co., Ltd. |
| Governing Rule | Article 791, paragraph 1, item 1; Article 801, paragraph 3, item 2; Article 189 of the Regulation for Enforcement of the Companies Act; Article 784, paragraph 2; Article 789; Article 799; and Article 923 of the Companies Act |
| Future plans | The company plans to apply for registration of the changes prescribed in Article 923 of the Companies Act without delay after 1 September 2026. |
Items this document does not state (5)
Decision-Making BodyPeriod CoveredQuantity / scaleImpact on Business PerformanceRelated previous disclosures
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The document states that, pursuant to the company split agreement, the rights and obligations relating to the NASH treatment app business were transferred to the wholly owned subsidiary. No other reason is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.